Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular ...
Nov 6, 2025 · The patent claims protect the composition of matter for Erasca’s potentially best-in-class pan-RAS molecular glue ERAS-0015 and related compositions until September 2043, which may be …
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...
Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …
Apr 28, 2026 · ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the …
Apr 27, 2026 · Erasca, Inc. (USA) announced on April 27, 2026, via a US Securities and Exchange Commission Form 8-K filing, that Revolution Medicines, Inc. (RevMed, USA) had transmitted a letter …
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular ...
Nov 6, 2025 · Erasca is evaluating ERAS -0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. ERAS -4001 is an oral, highly potent, and selective pan-KRAS inhibitor with a...
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data …
Apr 27, 2026 · ERAS -0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS...
Erasca secures worldwide rights to ERAS-0015 pan-RAS drug | ERAS …
Mar 10, 2026 · Erasca (Nasdaq: ERAS) exercised its option to expand the ERAS-0015 license with Joyo to include China, Hong Kong, and Macau, securing worldwide rights for the pan-RAS molecular glue.
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...
Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan ...
Mar 10, 2026 · ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 …